$772 Million is the total value of Johnson & Johnson Innovation - JJDC, Inc.'s 17 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 13.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FATE | Fate Therapeutics, Inc. | $278,604,000 | -9.3% | 3,379,064 | 0.0% | 36.08% | -8.9% | |
| ARWR | Arrowhead Pharmaceuticals | $216,228,000 | -13.6% | 3,260,869 | 0.0% | 28.00% | -13.2% | |
| PTGX | Protagonist Therapeutics Inc. | $63,434,000 | +28.5% | 2,449,183 | 0.0% | 8.22% | +29.0% | |
| LEGN | Legend Biotech Corporationsponsored ads | $47,279,000 | +3.1% | 1,629,173 | 0.0% | 6.12% | +3.5% | |
| VOR | New | Vor Biopharma, lnc. | $46,318,000 | – | 1,074,658 | +100.0% | 6.00% | – |
| MGTX | MeiraGTx Holdings plc | $41,826,000 | -4.7% | 2,898,550 | 0.0% | 5.42% | -4.3% | |
| FUSN | Fusion Pharmaceuticals Inc. | $39,348,000 | -8.8% | 3,670,516 | 0.0% | 5.10% | -8.4% | |
| PHGE | BiomX Inc. | $15,190,000 | +11.6% | 2,133,402 | 0.0% | 1.97% | +12.1% | |
| ACET | Buy | Adicet Bio, Inc. | $9,535,000 | +2.4% | 728,944 | +10.0% | 1.24% | +2.8% |
| PHAS | PhaseBio Pharmaceuticals, Inc. | $5,560,000 | +3.0% | 1,607,044 | 0.0% | 0.72% | +3.4% | |
| ALDX | Sell | Aldeyra Therapeutics, Inc. | $4,691,000 | +14.9% | 394,834 | -33.6% | 0.61% | +15.6% |
| SENS | Sell | Senseonics Holdings, Inc. | $1,300,000 | +183.8% | 492,269 | -6.3% | 0.17% | +184.7% |
| CSLT | Castlight Health Inc.cl b | $1,225,000 | +16.1% | 811,295 | 0.0% | 0.16% | +16.9% | |
| TCON | Tracon Pharmaceuticals, Inc. | $691,000 | -29.7% | 84,003 | 0.0% | 0.09% | -29.9% | |
| CBIO | Catalyst Biosciences, Inc. | $337,000 | -20.1% | 66,951 | 0.0% | 0.04% | -18.5% | |
| GRAY | New | Graybug Vision, Inc. | $275,000 | – | 49,547 | +100.0% | 0.04% | – |
| LUNG | Pulmonx Corporation | $258,000 | -33.7% | 5,639 | 0.0% | 0.03% | -34.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. | 7 | Q2 2021 | 74.6% |
| PROTAGONIST THERAPEUTICS INC. | 7 | Q2 2021 | 11.2% |
| BIOMX INC. | 7 | Q2 2021 | 8.1% |
| PHASEBIO PHARMACEUTICALS, INC. | 7 | Q2 2021 | 3.5% |
| ALDEYRA THERAPEUTICS, INC. | 7 | Q2 2021 | 1.2% |
| CASTLIGHT HEALTH INC. | 7 | Q2 2021 | 0.4% |
| SENSEONICS HOLDINGS, INC. | 7 | Q2 2021 | 0.2% |
| CATALYST BIOSCIENCES, INC. | 7 | Q2 2021 | 0.2% |
| TRACON PHARMACEUTICALS, INC. | 7 | Q2 2021 | 0.1% |
| MEIRAGTX HOLDINGS PLC | 6 | Q2 2021 | 21.2% |
View Johnson & Johnson Innovation - JJDC, Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-04-10 |
| 4 | 2024-03-06 |
| 13F-NT | 2024-02-14 |
| 3/A | 2024-02-02 |
| 4/A | 2024-02-02 |
| SC 13G | 2023-11-16 |
| 13F-NT | 2023-11-09 |
| 3 | 2023-09-18 |
| 3 | 2023-09-18 |
| 4 | 2023-09-18 |
View Johnson & Johnson Innovation - JJDC, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.